Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-2608 in PROS and Malformations Driven by PIK3CA Mutation
NCT06789913Phase 2Recruiting
- Sponsor
- Relay Therapeutics
- Start
- Jun 2025
- Primary completion
- Jul 2031
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of zovegalisib in PIK3CA-related overgrowth spectrum (PROS), Lymphatic Malformation (LM), vascular malformations (VM) and 4 more (8 arms), sponsored by Relay Therapeutics. Primary endpoints: Recommended Phase 2 Dose, Adverse Events and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
zovegalisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)Lymphatic Malformation (LM)vascular malformations (VM)Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies (CLOVES)Klippel-Trenaunay syndrome (KTS)
Beyond the preview
Go deeper on NCT06789913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789913.